ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit

Lancet. 2003 Oct 18;362(9392):1333; author reply 1334. doi: 10.1016/S0140-6736(03)14601-6.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Cisplatin / administration & dosage
  • Clinical Trials as Topic / economics
  • Clinical Trials as Topic / standards
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality
  • Paclitaxel / administration & dosage
  • Platinum Compounds / administration & dosage
  • Research Design / standards
  • Survival Analysis
  • Treatment Outcome

Substances

  • Platinum Compounds
  • Paclitaxel
  • Cisplatin